Compare Johnson Controls International PLC (JCI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Novartis AG — how do they compare? Johnson Controls International PLC trades at $157.38 (market cap $93.28B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 2.9× Johnson Controls International PLC's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and Novartis AG for 82 Days on average.
| JCI | NVS | |
|---|---|---|
Market Cap | $93.28B | $268.57B |
Volume | 2,786,476 | 1,532,573 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $168.62 |
52-Week Low | $105.55 | $121.80 |
Typical Hold Time | 65 Days | 82 Days |
Enterprise Value | $102.12B | $309.89B |
Dividend Yield | 1.04% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $157.44, up 0.97% on the day, reflecting strong momentum after beating earnings estimates for three consecutive quarters. The stock exhibits a bullish technical outlook, trading above key support levels, while fundamentals are supported by a 13.94% net income margin and robust ROE of 24.42%. Recent news highlights inclusion in AI industrial stock recommendations and strong Q3 2026 results with raised full-year guidance.
The outlook for JCI remains positive, driven by earnings outperformance and strong demand in thermal management and building systems. Key opportunities include expanding margins and strategic positioning in energy efficiency markets. Risks involve elevated valuation multiples and increasing debt-to-asset ratios, which could pressure the stock if growth moderates.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
